Geron (GERN) Q3 2024 earnings summary

Executive summary

• Achieved $28.2 million in net product revenue for RYTELO in its first full U.S. quarter (Q3 2024), surpassing expectations and reflecting strong demand across 388 ordering centers, about 45% of targeted accounts.

• RYTELO's commercial launch is supported by favorable payer coverage, with 70% of U.S.-covered lives having implemented medical coverage policies consistent with its FDA label; permanent J-code effective January 2025 to streamline reimbursement.

• Completed $250 million in gross proceeds from synthetic royalty and debt financings, with an additional $125 million available, and a $125 million upfront payment from Royalty Pharma for a capped revenue participation agreement.

• Cash, cash equivalents, and marketable securities stood at $378.9 million as of September 30, 2024; pro forma cash position is $542.4 million after recent financings and debt repayment.

• Preparing for potential EU launch of RYTELO, pending EMA approval expected in 2025, with commercialization in select EU markets targeted for 2026.

Financial highlights

• Q3 2024 net product revenue was $28.2 million; total net revenue was $28.3 million, up from $164,000 in Q3 2023, driven by RYTELO sales.

• Operating expenses for Q3 2024 were $56.5 million, up from $47.8 million in Q3 2023, reflecting higher commercial launch costs and increased headcount.

• Net loss for Q3 2024 was $26.4 million ($0.04/share), improved from $44.8 million ($0.08/share) in Q3 2023.

• Cash, cash equivalents, and marketable securities totaled $378.9 million as of September 30, 2024; pro forma $542.4 million after financings.

• Cost of goods sold for Q3 2024 was approximately $450,000; gross-to-net for Q3 was about 14%.

Outlook and guidance

• Full-year 2024 operating expenses expected to be $260–$270 million.

• Current cash position and anticipated revenues are expected to fund operations for at least the next 12 months, with scenarios where financing could take the company to profitability without further equity raises.

• Management expects net product revenue to increase through the remainder of 2024 as RYTELO launch progresses.

• Preparing for U.S. and potential EU commercial launches, completion of the ImpactMF trial, and supply chain investments.

• Phase 3 ImpactMF trial interim analysis anticipated in early 2026, with final analysis in early 2027.